OPINION

TOP STORIES

MEDICAL DEVICES

KEY THEMES

ARCHIVE & SEARCH

SIGN UP

LOG IN

COUNTRIES COVERED THIS MONTH

100 NEW stories in THIS MONTH
8.681 stories IN THE SITE since 2015

Forecasting & Launch Pricing Tool  

LIGHT - CONTENT AVAILABLE WITHOUT SUBSCRIPTION

 

KEY THEMES

 

About Akceso

Akceso Advisors A.G. offers professional support in the field of market patient access and pricing to the pharmaceutical industry. In the past decade, we had numerous success stories, delivering valuable market input for both leading pharmaceutical companies and SMEs worldwide. Our international team supports every client carrying out major-impact payer and pricing strategy projects, with the help of our state-of-the-art Verity Prices database and our cutting-edge international reference pricing tools.

CONTACT US:
Phone: +41 61 225 4393
Fax: +41 61 225 4391
Email: [email protected]
Website: https://akceso.ch/
Address: Akceso Advisors AG Aeschengraben 29. CH-4051 Basel Switzerland
Visit Our Website  

ABOUT THIS SITE

In our newsletter we provide a monthly view of developments in pricing, reimbursement, and market access across the globe. Since its launch in June 2015, we have covered more than 8,000 stories from over 100 countries. On this site, you can find all of the stories from the beginning and we update it monthly.

This is the Home page, here you can find the headlines of the recent news.

Already have an account?  Click on LOG IN button at the top of the page and enjoy the full functionality of the site! Read the full Opinion, the news extracts or use ARCHIVE & SEARCH page for all news in the past. 

Don't have an account yet?  Go to the "Light - Content available without subscription" section, you can read some selected news here. Use SIGN UP button at the top of the page to request access and use all features including opinion, archive and search.

Having any question, please contact us at [email protected]

Visit our website and read more about the features of our service!

READ MORE

OPINION

PROVING VALUE IN A POST-EXPERT WORLD

This edition of PRiMA headlines includes several stories related to obesity; not a surprise as Ozempic®, Mounjaro® etc. have become part of public consciousness. The key issue in pricing market access – reaching a fair, value-based and sustainable pricing approach – is likely to be even more controversial than the initial launch of Hepatitis C cures, given the prevalence of obesity globally. Whose truth will win the day?

Estimating the economic impact of obesity

In a study of the impact of obesity in Czechia, Greece, Hungary and Romania, chronic kidney disease and cardiovascular diseases were identified as the costliest obesity-related comorbidities (ORCs) with an annual cost burden per ORC exceeding $1,500 USD per patient per year. In Türkiye, chronic kidney disease, heart failure and ...

 

READ THE FULL ARTICLE

 

TOP STORIES

Forecasting & Launch Pricing Tool  

ASIA PACIFIC

 

EUROPE

 

LATIN AMERICA

 

MIDDLE EAST & AFRICA

 

NORTH AMERICA

 

MEDICAL DEVICES